PetVivo (OTCQB: PETV) Among MASK, XLAB, AASP Reports Joint Care Gains in Dogs, Cats and Horses w/ Spryng Osteoarthritis Findings

DALLAS TX, Oct. 19, 2026 - PetVivo Holdings, Inc. (OTCQB: PETV) announced two research abstracts evaluating Spryng Registered with OsteoCushion Registered Technology in rhesus macaques with naturally occurring osteoarthritis, adding preliminary mobility and tissue-response findings to its veterinary research program.

Alongside PetVivo Holdings, Inc. (OTCQB: PETV), other stocks on investors' watchlists include 3 E Network Tech Ltd. (NASDAQ: MASK), Exascale Labs (NASDAQ: XLAB), Agassi Sports Entertainment Corp. (OTC: AASP) and Atlantic American Corp. (NASDAQ: AAME), trading actively now,

Conducted with the Wisconsin National Primate Research Center at the University of Wisconsin-Madison, the research examines the company's collagen-elastin hydrogel administered directly into affected joints. One study selected 18 macaques and reported statistically significant walking-speed improvements versus baseline during the first three weeks following treatment. Additional mobility analyses remain underway.

A separate investigation involving four macaques identified hydrogel incorporation into the joint-lining membrane by day 11, with minimal associated inflammatory cells. These early observations support further investigation; longer-term outcomes and relevance to other species remain unestablished.

The findings are scheduled for presentation at the Association of Primate Veterinarians Workshop on October 23, the AALAS National Meeting on October 28, and the American College of Veterinary Pathologists Annual Meeting in November. The presentations provide opportunities for scientific discussion as further analyses continue.

Building on Earlier Canine Research and Veterinary Outreach

The announcement follows PetVivo's planned Spryng exhibit at the October 8-10 ACVS Surgery Summit in Charlotte, part of a broader conference program aimed at veterinary surgeons, specialists and practice owners. Spryng is commercially available for managing lameness and joint-related conditions, including osteoarthritis, in dogs, cats and horses.

Earlier research published in Veterinary Record evaluated 40 client-owned dogs receiving a single injection and followed for 84 days. Twenty-two dogs-55% of those enrolled-met a threshold of at least 25% improvement on the modified Glasgow Composite Pain Scale. The company-funded proof-of-concept study lacked a control group, blinding and objective lameness measurements, and investigators recommended further objective research.

Together, the developments expand the scientific information available to veterinarians evaluating Spryng. For investors, further research, adoption by veterinary practices and repeat purchasing remain meaningful measures of progress toward sustained commercial growth.

About the Company

PetVivo Holdings, Inc., through PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., develops and commercializes medical devices, biomaterials and therapeutics for animal and human health. Its lead commercial product is Spryng Registered with OsteoCushion Registered Technology.

About The Street Reports

The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=petvivo-otcqb-petv-among-mask-xlab-aasp-reports-joint-care-gains-in-dogs-cats-and-horses-w-spryng-osteoarthritis-findings]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.